all-P-ambo-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'?5')-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'?5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'?5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'?5')-2'-O-(2-methoxyethyl)-5-methyl-Pthiouridylyl-( 3'?5')-P-thiothymidylyl-(3'?5')-P-thiothymidylyl-(3'?5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'?5')-Pthiothymidylyl-( 3'?5')-P-thiothymidylyl-(3'?5')-2'-deoxy-Pthioadenylyl-( 3'?5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'?5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'?5')-2'-O-(2-methoxyethyl)-Pthioadenylyl-( 3'?5')-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'?5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'?5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'?5')-2'-O-(2-methoxyethyl)-5-methyluridine
Mild Cognitive Impairment Due to Alzheimer's Disease
Biogennucleic_acidPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
316 Active assets in the Mild Cognitive Impairment Due to Alzheimer's Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE Akiva Mintz | Phase 4 | BBB |
Namenda Carnot Laboratories | Phase 4 | BBB |
Cipralex NYU Langone Health | Phase 4 | BBB |
Rivastigmine Anhui Provincial Hospital | Phase 4 | BBB |
Sertraline AstraZeneca | Phase 4 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →